高剂量异烟肼在海地耐多药结核病治疗中的改善结局。
Improved Outcomes With High-dose Isoniazid in Multidrug-resistant Tuberculosis Treatment in Haiti.
机构信息
Center for Global Health, Weill Cornell Medicine, New York City, New York.
The Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections, Port-au-Prince, Haiti.
出版信息
Clin Infect Dis. 2019 Aug 1;69(4):717-719. doi: 10.1093/cid/ciz039.
Abstract
We report outcomes for a cohort of patients with multidrug-resistant tuberculosis who received high-dose isoniazid in Haiti. Patients who received high-dose isoniazid had a faster time to culture conversion and higher odds of successful outcome, despite high-level isoniazid resistance. This suggests high-dose isoniazid may have effectiveness even with phenotypic resistance.
摘要
我们报告了在海地接受高剂量异烟肼治疗的耐多药结核病患者队列的结果。尽管存在高水平异烟肼耐药性，但接受高剂量异烟肼治疗的患者培养转换时间更快，成功结局的可能性更高。这表明高剂量异烟肼即使存在表型耐药性也可能具有疗效。
相似文献
1
Improved Outcomes With High-dose Isoniazid in Multidrug-resistant Tuberculosis Treatment in Haiti.高剂量异烟肼在海地耐多药结核病治疗中的改善结局。
Clin Infect Dis. 2019 Aug 1;69(4):717-719. doi: 10.1093/cid/ciz039.
2
[Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].[耐异烟肼或耐利福平结核病的特征及治疗结果]
Kekkaku. 2003 Oct;78(10):611-7.
3
A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis.高剂量异烟肼辅助治疗耐多药结核病的随机对照试验。
Int J Tuberc Lung Dis. 2008 Sep;12(9):1102; author reply 1102.
4
Prevalence of isoniazid resistance-conferring mutations associated with multidrug-resistant tuberculosis in Free State Province, South Africa.南非自由州省与耐多药结核病相关的异烟肼耐药突变体的流行情况。
S Afr Med J. 2019 Aug 28;109(9):659-664. doi: 10.7196/SAMJ.2019.v109i9.13730.
5
[The therapeutic effect of regimens containing isoniazid and rifampicin for pulmonary tuberculosis with single isoniazid or rifampicin resistance].含异烟肼和利福平方案对单耐异烟肼或利福平肺结核的治疗效果
Zhonghua Jie He He Hu Xi Za Zhi. 2014 Dec;37(12):915-8.
6
Predictors of time to unfavorable treatment outcomes among patients with multidrug resistant tuberculosis in Oromia region, Ethiopia.预测埃塞俄比亚奥罗米亚地区耐多药结核病患者不良治疗结局的时间的因素。
PLoS One. 2019 Oct 30;14(10):e0224025. doi: 10.1371/journal.pone.0224025. eCollection 2019.
7
Prevalence and factors associated with multidrug-resistant tuberculosis in South India.印度南部耐多药结核病的流行情况及相关因素。
Sci Rep. 2020 Oct 16;10(1):17552. doi: 10.1038/s41598-020-74432-y.
8
Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries.耐多药结核病的标准短程化疗：6个国家的治疗结果
JAMA. 2000 May 17;283(19):2537-45. doi: 10.1001/jama.283.19.2537.
9
Can a nine-month regimen be used to treat isoniazid resistant tuberculosis diagnosed after standard treatment is started?在开始标准治疗后被诊断出的耐异烟肼结核病，能否使用为期九个月的治疗方案进行治疗？
J Infect. 2001 Jan;42(1):1-3. doi: 10.1053/jinf.2000.0773.
10
Evolving rifampicin and isoniazid mono-resistance in a high multidrug-resistant and extensively drug-resistant tuberculosis region: a retrospective data analysis.在一个高耐多药和广泛耐药结核地区，利福平及异烟肼单耐药的演变：回顾性数据分析。
BMJ Open. 2019 Nov 6;9(11):e031663. doi: 10.1136/bmjopen-2019-031663.
引用本文的文献
1
Risk Prediction Model for Isoniazid Dosing in Tuberculosis Meningitis Patients in Southwest China.中国西南地区结核性脑膜炎患者异烟肼给药的风险预测模型
Int J Gen Med. 2024 Dec 20;17:6407-6419. doi: 10.2147/IJGM.S498828. eCollection 2024.
2
Precision Medicine Strategies to Improve Isoniazid Therapy in Patients with Tuberculosis.精准医学策略改善结核病患者的异烟肼治疗。
Eur J Drug Metab Pharmacokinet. 2024 Sep;49(5):541-557. doi: 10.1007/s13318-024-00910-7. Epub 2024 Aug 17.
3
Comprehensive Therapeutic Approaches to Tuberculous Meningitis: Pharmacokinetics, Combined Dosing, and Advanced Intrathecal Therapies.结核性脑膜炎的综合治疗方法：药代动力学、联合给药及鞘内高级治疗
Pharmaceutics. 2024 Apr 14;16(4):540. doi: 10.3390/pharmaceutics16040540.
4
High-Dose Isoniazid Lacks EARLY Bactericidal Activity against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized Phase II Clinical Trial.高剂量异烟肼缺乏对 katG 突变介导的耐异烟肼结核病的早期杀菌活性：一项随机、Ⅱ期临床试验。
Am J Respir Crit Care Med. 2024 Aug 1;210(3):343-351. doi: 10.1164/rccm.202311-2004OC.
5
The efficacy and safety of high-dose isoniazid-containing therapy for multidrug-resistant tuberculosis: a systematic review and meta-analysis.含高剂量异烟肼治疗耐多药结核病的疗效与安全性：一项系统评价与荟萃分析
Front Pharmacol. 2024 Jan 8;14:1331371. doi: 10.3389/fphar.2023.1331371. eCollection 2023.
6
Quantitative measurement of antibiotic resistance in Mycobacterium tuberculosis reveals genetic determinants of resistance and susceptibility in a target gene approach.定量测量结核分枝杆菌中的抗生素耐药性，揭示了目标基因方法中耐药性和敏感性的遗传决定因素。
Nat Commun. 2024 Jan 12;15(1):488. doi: 10.1038/s41467-023-44325-5.
7
Quantitative measurement of antibiotic resistance in reveals genetic determinants of resistance and susceptibility in a target gene approach.抗生素耐药性的定量测量揭示了基于靶基因方法的耐药性和敏感性的遗传决定因素。
Res Sq. 2023 Oct 2:rs.3.rs-3378915. doi: 10.21203/rs.3.rs-3378915/v1.
8
Isoniazid resistance-conferring mutations are associated with highly variable phenotypic resistance.赋予异烟肼耐药性的突变与高度可变的表型耐药性相关。
J Clin Tuberc Other Mycobact Dis. 2023 Jul 26;33:100387. doi: 10.1016/j.jctube.2023.100387. eCollection 2023 Dec.
9
The Changing Paradigm of Drug-Resistant Tuberculosis Treatment: Successes, Pitfalls, and Future Perspectives.耐药结核病治疗范式的转变：成功、陷阱与未来展望。
Clin Microbiol Rev. 2022 Dec 21;35(4):e0018019. doi: 10.1128/cmr.00180-19. Epub 2022 Oct 6.
10
Time to Culture Conversion of Bedaquiline and High-Dose Isoniazid for Drug-Resistant Tuberculosis.用于耐药结核病的贝达喹啉和高剂量异烟肼的培养转化时间
Open Forum Infect Dis. 2022 Aug 29;9(9):ofac440. doi: 10.1093/ofid/ofac440. eCollection 2022 Sep.
本文引用的文献
1
Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs.耐多药结核病项目中高剂量利福平、异烟肼和吡嗪酰胺治疗的中敏剂量依赖性折点。
Clin Infect Dis. 2018 Nov 13;67(11):1743-1749. doi: 10.1093/cid/ciy346.
2
Rationale for high-dose isoniazid in the treatment of multidrug-resistant tuberculosis.大剂量异烟肼治疗耐多药结核病的理论依据。
Int J Tuberc Lung Dis. 2017 Jan 1;21(1):123-124. doi: 10.5588/ijtld.16.0619.
3
Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis.老药新用：改造现有药物以优化耐药结核病治疗。
Clin Infect Dis. 2012 Aug;55(4):572-81. doi: 10.1093/cid/cis487. Epub 2012 May 21.
4
Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy.临床研究的荟萃分析支持获得性耐药和抗结核治疗失败的药代动力学变异性假说。
Clin Infect Dis. 2012 Jul;55(2):169-77. doi: 10.1093/cid/cis353. Epub 2012 Mar 30.
5
Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa.南非西开普省耐异烟肼结核病患者的治疗结果。
Clin Infect Dis. 2011 Aug;53(4):369-72. doi: 10.1093/cid/cir406.
6
Tuberculosis drug resistance in an area of low endemicity in 2004 to 2006: semiquantitative drug susceptibility testing and genotyping.2004年至2006年低流行地区的结核病耐药性：半定量药物敏感性检测和基因分型
J Clin Microbiol. 2008 Dec;46(12):4064-7. doi: 10.1128/JCM.01114-08. Epub 2008 Oct 15.
7
A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis.高剂量异烟肼辅助治疗耐多药结核病的随机对照试验。
Int J Tuberc Lung Dis. 2008 Feb;12(2):139-45.
Zotero 插件